IL1RA inhibits the progression of oral squamous cell carcinoma by mediating type Ⅰ interferon response
Interleukin-1 receptor antagonist (IL1RA) is an anti-inflammatory and anti-tumor protein, and a member of the Interleukin-1 (IL-1) family. Our previous finding showed that IL1RA is a tumor marker for oral squamous cell carcinoma (OSCC), but the exact mechanism is unknown. The present study aims to i...
Saved in:
| Main Authors: | Yujie Ding, Yufei Shan, Jiaqi Gu, Jie Yi, Zhida Sun |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325001597 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01) -
Rapid achievement of low disease activity during the use of a type I interferon inhibitor in a patient with torpid systemic lupus erythematosus (case report)
by: A. A. Baranov, et al.
Published: (2024-06-01) -
Stimulator of Interferon Genes (STING)-Type I Interferon Signaling: Bridging Immunity and Pain
by: Ti-Chuan Chiu, et al.
Published: (2025-06-01) -
PREVALENCE OF SIDE EFFECTS OF INTERFERON THERAPY IN CHILDREN WITH CHRONIC VIRAL HEPATITIS C
by: T. A. Skvortsova, et al.
Published: (2013-05-01) -
Efficacy and safety of the type I interferon receptor inhibitor anifrolumab in patients with systemic lupus erythematosus (results of a 6-month study)
by: T. M. Reshetnyak, et al.
Published: (2024-04-01)